We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 2.83 | 1.55% | 185.00 | 186.85 | 182.11 | 183.85 | 6,948,834 | 01:00:00 |
From Jul 2023 to Jul 2024
By Colin Kellaher
AbbVie has agreed to buy ImmunoGen for about $10.1 billion in a deal that speeds the biopharmaceutical company's entry into the commercial market for ovarian cancer.
AbbVie on Thursday said it will pay $31.26 a share in cash for ImmunoGen, a roughly 95% premium to Wednesday's closing price of $16.06 for the Waltham, Mass., pharmaceutical company.
With the deal, AbbVie will acquire ImmunoGen's flagship cancer therapy Elahere, a first-in-class antibody-drug conjugate, or ADC, approved for platinum-resistant ovarian cancer.
AbbVie, based in North Chicago, Ill., said ImmunoGen's follow-on pipeline of ADCs complements its own ADC platform and its existing programs.
AbbVie said it expects to complete the acquisition in the middle of 2024.
Trading in shares of ImmunoGen was halted premarket on Thursday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 30, 2023 07:58 ET (12:58 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
